Searched for
SAROGLITAZAR
Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%Zydus Lifesciences reported a 29% year-on-year rise in Q2FY27 revenue to Rs 7,909 crore, driven by growth across key markets and a 76% surg...- Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil PatelZydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to f...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trialZydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver diseas...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS...
- Torrent, Zydus in co-marketing pact for liver disease drug SaroglitazarTorrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment...
- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...
- Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar MgLupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by Ind...
- Zydus starts trial to generate data on effect of Saroglitazar Mg in NAFLD patientsZydus Lifesciences has launched a real-world data registry trial to determine the benefits of its liver drug, Saroglitazar Magnesium, on pa...
- European Medicines Agency grants Orphan Drug Designation to Zydus Cadila's Saroglitazar MgOrphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or ch...
- USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar MgZydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, includ...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- Zydus Cadila gets USFDA Fast Track Designation for SaroglitazarDrug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug c...
- Zydus Cadila files NDA for Saroglitazar MagnesiumNASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...
- Zydus gets USFDA nod for phase II trials of liver drugThis development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies.
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...
Load More
